Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;83(9):807-818.
doi: 10.1007/s40265-023-01868-7. Epub 2023 Apr 21.

Eftrenonacog Alfa: A Review in Haemophilia B

Yvette N Lamb  1 , Sheridan M Hoy  2
Affiliations
Review

Eftrenonacog Alfa: A Review in Haemophilia B

Yvette N Lamb et al. Drugs. 2023 Jun.

Erratum in

Abstract

Eftrenonacog alfa (Alprolix®) is an extended half-life recombinant factor IX (rFIX)-Fc fusion protein (hereafter referred to as rFIXFc). Administered as an intravenous bolus, it is approved for prophylactic use and the treatment of bleeding in patients with haemophilia B in various countries worldwide, including those of the EU, as well as the USA. In multinational, phase III trials, rFIXFc was effective for the prophylaxis, perioperative management or on-demand treatment of bleeding in male patients with severe haemophilia B regardless of age and irrespective of whether or not they had been previously treated with FIX replacement products. Prophylactic efficacy was maintained over the longer term (up to 5 years) in previously treated patients. rFIXFc effectiveness in the real-world setting is supported by results of prospective studies, as well as the outcomes of several retrospective trials. rFIXFc was well tolerated in clinical trials in previously treated and untreated children, adolescents and/or adults with severe haemophilia B. Thus, rFIXFc continues to represent a useful treatment option among the haemophilia B patient population.

Plain language summary

Haemophilia B is a rare inherited bleeding disorder caused by a deficiency in coagulation factor IX (FIX). Its management involves rectifying the deficiency in FIX by administering an FIX replacement product, thereby increasing FIX activity and reducing bleeding. FIX replacement therapy can be administered at the time of bleeding (i.e. as on-demand treatment) or prophylactically (as scheduled injections), as well as before surgery. Eftrenonacog alfa (also known as rFIXFc; Alprolix®) is a replacement FIX therapy comprising FIX linked to a region of human immunoglobulin G to prolong the half-life of the product. It has been approved for the prevention and treatment of bleeding in patients with haemophilia B in various countries worldwide. Designed to require less frequent injections, rFIXFc was effective and well tolerated when used to prevent or treat bleeding, including before surgery, in individuals with haemophilia B regardless of age or whether they have been treated previously with an FIX replacement product. Thus, rFIXFc continues to represent a useful treatment option for individuals with haemophilia B.

PubMed Disclaimer

Conflict of interest statement

Yvette N. Lamb and Sheridan M. Hoy are salaried employees of Adis International Ltd/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

References

    1. Dolan G, Benson G, Duffy A, et al. Haemophilia B: where are we now and what does the future hold? Blood Rev. 2018;32:52–60. doi: 10.1016/j.blre.2017.08.007. - DOI - PubMed
    1. Hart DP, Matino D, Astermark J, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022;13:1–22. doi: 10.1177/20406207221085202. - DOI - PMC - PubMed
    1. Nazeef M, Sheehan JP. New developments in the management of moderate-to-severe hemophilia B. J Blood Med. 2016;7:27–38. - PMC - PubMed
    1. Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol. 2018;9(11):335–346. doi: 10.1177/2040620718802606. - DOI - PMC - PubMed
    1. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–197. doi: 10.1016/S0140-6736(15)01123-X. - DOI - PubMed